Short Interest in PolyPid Ltd. (NASDAQ:PYPD) Expands By 235.2%

PolyPid Ltd. (NASDAQ:PYPD) was the recipient of a large increase in short interest during the month of July. As of July 15th, there was short interest totaling 283,206 shares, an increase of 235.2% from the June 30th total of 84,501 shares. Based on an average daily volume of 255,249 shares, the days-to-cover ratio is presently 1.1 days. Approximately 2.0% of the company’s shares are sold short.

PolyPid Price Performance

Shares of PolyPid stock traded down $0.34 on Friday, hitting $3.90. 286,401 shares of the company’s stock traded hands, compared to its average volume of 349,662. The company has a fifty day moving average of $4.84 and a two-hundred day moving average of $4.58. PolyPid has a one year low of $3.06 and a one year high of $5.73. The company has a market capitalization of $74.41 million, a price-to-earnings ratio of -2.04 and a beta of 1.40.

PolyPid (NASDAQ:PYPD) last issued its earnings results on Wednesday, May 13th. The company reported ($0.35) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.12. Equities research analysts anticipate that PolyPid will post -0.77 earnings per share for the current year.

Institutional Trading of PolyPid

Large investors have recently modified their holdings of the stock. AIGH Capital Management LLC increased its stake in shares of PolyPid by 26.1% in the 4th quarter. AIGH Capital Management LLC now owns 1,342,972 shares of the company’s stock valued at $5,828,000 after acquiring an additional 277,844 shares in the last quarter. XTX Topco Ltd boosted its stake in PolyPid by 50.0% during the fourth quarter. XTX Topco Ltd now owns 32,661 shares of the company’s stock worth $142,000 after acquiring an additional 10,888 shares in the last quarter. ADAR1 Capital Management LLC bought a new position in PolyPid during the fourth quarter worth $451,000. Renaissance Technologies LLC acquired a new stake in PolyPid in the first quarter worth $81,000. Finally, Jane Street Group LLC acquired a new stake in PolyPid in the fourth quarter worth $66,000. Institutional investors and hedge funds own 26.47% of the company’s stock.

Key Stories Impacting PolyPid

Here are the key news stories impacting PolyPid this week:

• Positive Sentiment: HC Wainwright reaffirmed a Buy rating on PolyPid and maintained a $13 price target, signaling continued confidence in the stock’s longer-term potential. The firm also slightly raised its Q2 2026 EPS estimate and Q4 2026 EPS estimate, which may help support sentiment. Article Title
• Neutral Sentiment: HC Wainwright made several forecast adjustments for future years, with some estimates improving and others declining. The changes suggest analysts still see meaningful uncertainty in PolyPid’s earnings path, but not a major shift in the overall investment thesis.
• Negative Sentiment: Short interest in PolyPid (PYPD) rose sharply in July to 283,206 shares, up 235.2% from late June, with about 2.0% of shares sold short. Rising short interest can indicate growing skepticism among traders and may weigh on the stock. Article Title
• Negative Sentiment: HC Wainwright cut its FY2027, FY2028, FY2029, and FY2030 EPS estimates for PolyPid, including a sizeable reduction to FY2030 expectations. Lower long-term earnings forecasts can pressure valuation expectations, even though the firm kept its bullish rating. Article Title

Analyst Ratings Changes

A number of equities research analysts have recently commented on the stock. Weiss Ratings raised shares of PolyPid from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, June 23rd. Craig Hallum set a $12.00 target price on shares of PolyPid in a research note on Wednesday. Finally, HC Wainwright restated a “buy” rating and issued a $13.00 target price on shares of PolyPid in a report on Tuesday, July 21st. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, PolyPid presently has an average rating of “Moderate Buy” and a consensus target price of $11.33.

About PolyPid

PolyPid Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.